As of December 31, 2022, MoonLake held cash, cash equivalents and short-term marketable debt securities of $72.1M, compared to $83.5M as of September 30, 2022, corresponding to a cash burn of $11.4M in the fourth quarter which was primarily driven by net cash used in operating activities. Matthias Bodenstedt, CFO said: "2022 provided us with a very strong financial platform to rapidly and efficiently pursue the clinical development of sonelokimab, building on the promising results already observed in the Phase 2b psoriasis trial. We remain in excellent financial health with a strong balance sheet providing a cash runway into 2H 2024 and at least 12 months beyond expected key readouts. This is on plan with our financial roadmap. MoonLake remains lean, efficient, and well-funded to deliver its goals."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MLTX:
- MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics management to meet with Cantor Fitzgerald
- Cantor biopharma/biotech analysts hold analyst/industry conference call
- MoonLake Immunotherapeutics initiated with a Buy at BTIG
- MoonLake initiated with an Overweight at Cantor Fitzgerald